ISMRC 2023 Final Programme

23 Tuesday, 2 May 2023 – Poster Sessions PS-02-003 Host transcriptome signatures in hu- man fecal-washes predict histological remission in IBD patients Keren Bahar-Halpern, Israel PS-02-004 Monitoring treatment efficacy using personalised circulating-tumour DNA panels in patients with metastatic breast cancer Pia Mouhanna, Sweden PS-02-005 TNC positive extracellular vesicles as clinical biomarkers in glioblastoma Amanda Salviano da Silva, Germany PS-02-006 Liquid biopsy in colorectal cancer bey- ond targeted analysis of single variants Ariane Hallermayr, Germany PS-02-007 Transcriptomic analysis of circulating tumor cells in metastatic breast cancer: the new frontiers of liquid biopsy for personalized medicine Tania Rossi, Italy PS-02-008 Single-center prospective study to evaluate circulating tumor cells as a monitoring tool in women with early breast cancer treated with neoadjuvant chemotherapy Jee Hung Kim, Republic of Korea PS-02-009 Deep learning for Circulating Tumor Cell (CTC) identification with the CELL- SEARCH system: towards optimal stan- dardization Luca Biasiolli, Italy PS-02-010 It’s a match – circulating tumor DNA in urine and plasma reveal complementary information in prostate cancer Tina Moser, Austria PS-02-011 ctDNA testing in treatment response monitoring of patients with metastatic colorectal cancer: the DOLPHIN study Denise van Steijn, The Netherlands PS-02-012 Characterisation of candidate WHO 1 st International standard materials for cancer biomarkers Leandro Lo Cascio, United Kingdom PS-02-013 Advancing Single-Cell Proteomics with ZeptoCTC: A High-Sensitivity Method for Analysis of Circulating Tumor Cells Mahdi Rivandi, Germany PS-02-014 Comparison of DNA reference mate- rial for pre-analytics: Nucleosomal plasma-spike-ins reveal true recovery efficiencies of circulating cell-free DNA extractions Tu Truong, Germany PS-02-015 Spotting the difference: rare cell cha- racterization by multiplex mRNA in situ hybridization and machine learning in the context of liquid biopsy-based the- rapy resistance monitoring Lilli Bonstingl, Austria